-Reuters
Cowen & Co. Downgrades Fate Therapeutics to Market Perform
Cowen & Co. analyst Tyler Van Buren downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Market Perform.
Related Posts
RADA Adds $24M New Business In Q3; Reiterates FY21 Revenue Outlook
Rada Electronic Industries Ltd (NASDAQ:RADA) reports receipt of $24 million in new business in 3Q21. The total amount of new…
FedEx Q1 Adj. EPS $4.37 Misses $5.00 Estimate, Sales $22.00B Beat $21.91B Estimate
FedEx (NYSE:FDX) reported quarterly earnings of $4.37 per share which missed the analyst consensus estimate of $5.00 by 12.6 percent. This is a 10.27 percent decrease over earnings of $4.87 per share from the same period
